North America Viral Vector Manufacturing Market Report and Forecast 2024-2032

North America Viral Vector Manufacturing Market Outlook

The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023, driven by the increased funding for the development of gene therapies in the region. The market is expected to grow at a CAGR of 7.16% during the forecast period of 2024-2032, with the values likely to rise from USD 4.5 billion in 2024 to USD 7.9 billion by 2032.

Key Takeaways

• In November 2023 , Genezen secured USD 18.5 million funding to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to its growing clientele of cell and gene therapy innovators.

• The North America viral vector manufacturing market share is significantly impacted by the rising preference for personalised medicines to tackle chronic diseases.

• In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Located at Plainville, Massachusetts, the development is projected to boost viral vector production as well as gene therapy production.

In North America, the market is witnessing steady growth driven by the rising demand for gene therapy, vaccines, and other innovative therapeutics to tackle the growing burden of genetic disorders, chronic diseases, and infectious diseases, among others. Viral vectors such as adeno-associated viruses, adenoviruses, and lentiviruses are increasingly employed for gene transfer in gene therapy. The substantial funding for the development of gene therapies is expected to drive the North America viral vector manufacturing market growth in the forecast period. In November 2023 , a study published in Nature estimated the annual spending on gene therapy to be USD 20.4 billion in the United States. This rising investment in the biotechnology sector is likely to boost the market size.

One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players supported by major financial investments. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing led by Ampersand Capital Partners which aimed to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to their cell and gene therapy innovators. Such investments are also poised to foster technological innovation and expansion of manufacturing sites and is expected to meet the growing North America viral vector manufacturing market demand.

In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Situated at Plainville, Massachusetts, the company intended to make use of its 400,000 square feet viral vector manufacturing unit to boost viral vector production along with gene therapy production simultaneously. These initiatives mark as one of the most impactful North America viral vector manufacturing market trends, expected to help in accelerating the development and commercialization of life-saving therapies which will ultimately impact the market dynamics.

Other factors that influence the market share include the advancement in the healthcare infrastructure, increased research efforts aimed at finding novel therapeutics, and the improvement in regulatory reforms.

North America Viral Vector Manufacturing Market Segmentation

North America viral vector manufacturing market analysis include a detailed breakup of the market based on the following segments:

North America Viral Vector Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Charles River Laboratories

• Finvector

• Kaneka Eurogentec SA

• Merck KGaA

• UniQure NV

• Oxford Biomedica PLC

• AstraZeneca

• Vibalogics

• Sanofi

• F.Hoffmann-La Roche Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report